The Endpoints 100 survey: CEOs changed the way biotechs operate during the pandemic. Things will never be the same again

With the US at the front of the line for new Covid-19 vaccines, the biotech industry is looking at the near-term end of the pandemic — or at least a more manageable easing of the rules established during the lockdown. But only a relative handful of CEOs expect things to...

Click to view original post